Elicio Therapeutics (ELTX) Convertible Debt (2024)
Elicio Therapeutics' (ELTX) quarterly Convertible Debt came in at $20.0 million in Q4 2024, up 1.0% quarter-over-quarter from $19.8 million in Q3 2024.
Powered by 
Analysis
Elicio Therapeutics (ELTX) Convertible Debt (2024) Analysis & Trends
Elicio Therapeutics (ELTX) has reported Convertible Debt for 1 consecutive years, with $20.0 million the latest figure, recorded in Q4 2024.
- For the quarter ending Q4 2024, Convertible Debt changed N/A year-over-year to $20.0 million; the trailing twelve-month figure through Dec 2024 stood at $20.0 million (changed N/A YoY), and the FY2024 full-year result was $20.0 million, changed N/A from the prior year.
- Convertible Debt improved to $20.0 million in Q4 2024 per ELTX's latest filing, from $19.8 million in the prior quarter.
- Across five years, Convertible Debt topped out at $20.0 million in Q4 2024 and bottomed at $19.8 million in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Elicio Therapeutics | 40.60 Mn | 17.10 Mn | - |